Gholami, Sepideh
Abidalhassan, Mustafa
Cho, May
Saeed, Anwaar
Rocha, Flavio G.
Article History
Accepted: 26 June 2022
First Online: 19 July 2022
Declarations
:
: Not applicable.
: Not applicable.
: AS reports research grants (to institution) from AstraZeneca, Bristol Myers Squibb, Merck, Clovis, Exelixis, Actuate Therapeutics, Incyte Corporation, Daiichi Sankyo, Five Prime Therapeutics, Amgen, Innovent Biologics, Dragonfly Therapeutics, KAHR Medical, Biontech, and advisory board fees from AstraZeneca, Bristol Myers Squibb, Exelixis, Pfizer, and Daiichi Sankyo. FGR reports Consultant-Medtronic, Oncosil; Advisory Board, Astra Zeneca; Research Funding, Gunze. MC reports Speaker’s Bureau for Pfizer, Natera, Taiho, BMS, AstraZeneca, DSI; Advisory Board and Honoraria for Amgen, Incyte, Eisai, Ipsen, Astellas, Taiho, Exelixis, QED, I-Mab, Tempus, Seattle Genetics, HelioDx, Bayer, AstraZeneca, Genentech/Roche, Pfizer, Natera, Taiho, BMS, Basilea. SG report Consulting or Advisory Board for Signatera, QED Therapeutics, TRUSELTIQ; Speakers’ Bureau for Helsinn Therapeutics. MA has no relevant financial or non-financial interests to disclose.